Oxford University to trial giving AstraZeneca Covid vaccine as a nasal spray with the hope it will trigger a better and faster immune response in the lungs

AstraZeneca’s coronavirus vaccine will be administered as a nasal spray as part of a new trial.

Oxford University scientists — who developed the jab — have been looking at injection-free ways to dish out the vaccine.

It’s thought that nasal sprays may better target immune cells in the lungs, throat and nose, making them even more effective at defending against Covid.

Oxford is looking for 30 adults to get the vaccine squirted up their noses as soon as next week. 

Volunteers will be tracked for four months to see make sure it’s safe as part of the initial trial.

If successful, the phase one study will move on and tens or potentially hundreds more adults will be recruited to see if it can ward off the virus as well as a jab.

Nasal spray vaccines would be great news for people who have a fear of needles and could alleviate supply issues that have hindered rollouts around the world. This method is already used to give out children’s flu jabs.  

Oxford university will trial administering the AstraZeneca vaccine through a nasal spray as part of trials that could start as soon as next week

The university’s study, involving adults over 40, is part of its partnership with AstraZeneca, the Financial Times reported.  

Professor Sarah Gilbert, one of the lead scientists behind the Oxford university jab, announced last month that her team was working on injection-free ways of delivering the vaccine.